0

Close
 
Upcoming Allied Market Research
2023
Nanomedicine For Drug Delivery Market

Nanomedicine for Drug Delivery Market

by Modality (Diagnostics, Treatments), by Product Type (Nanoparticles, Nano-shells, Nanotubes, Nanodevices), by Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, Others) and by End User (Hospitals, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A12299
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Nanomedicine For Drug Delivery Market

Request Now !

Nanoparticle that is employed in drug delivery is often called nanomedicine. Nano delivery systems and nanomedicines are relatively new but are developing rapidly. In nanomedicine, various materials in the nanoscale range are used to deliver different therapeutic agents to targeted sites in the body in a controlled manner. Nanomedicines are target-oriented, site-specific that help deliver medicines precisely. Different applications of nanomedicine for drug delivery are found these days as they are often used as biological agents, chemotherapeutic agents, and immunotherapeutic agents. In addition, nanomedicines remain in circulation for a prolonged period and also enable the release of drugs at a specific dose. 

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in December, 2019. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

With COVID-19, the supply chain of the raw materials required to manufacture nanomedicine for drug delivery has been disrupted in many countries. In addition, the market growth of nanomedicine for drug delivery is also declining as their manufacturers have slowed down their production because of the pandemic. Therefore, COVID 19 is expected to have a significant impact on the nanomedicine for drug delivery market.

Top Impacting Factors

The surging prevalence of diseases like cancer is likely to propel the growth of nanomedicine for the drug delivery market. Many therapies are currently in pipeline to assist in the treatment of cancer with the use of nanomedicine for proper drug delivery.

The rise in number of people dying from cardiovascular diseases is surging the demand for nanomedicine for drug delivery technology. Hence, this is acting as one of the factors behind the growth of the market.

Demand for novel therapies in treating neurological diseases such as Parkinson's disease, brain tumors, and Alzheimer's disease can further help grow the nanomedicine for drug delivery market.

However, the cost of nanotechnology drug delivery systems for nanosystem is unbearable for people living in developing countries. This factor can impede the growth of nanomedicine for the drug delivery market.

Key Market Trends

FDA- approved therapeutic nanoparticles for various chronic diseases like cancer are currently being developed for reformulating combinations of chemotherapy drugs with polymeric nanoparticles.

North America leads the market of nanomedicine for drug delivery owing to the presence of growing partnerships among major organizations with nanomedicine startup companies. In addition, a number of companies in this region are also focused on developing nanomedicines for cancer treatment.

In Asia-Pacific, nanomedicine for drug delivery market is also expected to expand at a significant rate during the forecast period because of the rise in demand for prophylaxis of chronic diseases and an increased number of research grants by the government.

With increased assistance from the government in funding R&D activities all over the world, the nanomedicine for drug delivery market is expected to find a major share during the forecast period, when it comes to treating neurological disorders such as Parkinson’s disease. 

Key Benefits of the Report

  • This study presents the analytical depiction of the nanomedicine for the drug delivery industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the nanomedicine for drug delivery market share.
  • The current market is quantitatively analyzed to highlight the growth scenario of the nanomedicine for drug delivery market.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Nanomedicine for Drug Delivery Report

  • Which are the leading players active in the nanomedicine for drug delivery market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the nanomedicine for drug delivery market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps in the market?
  • What are the impacts of COVID-19 on the industry?
  • What is nanomedicine for drug delivery?
  • What are the current and predicted trends of the market?

 Nanomedicine for Drug Delivery Market Report Highlights

Aspects Details
By Modality
  • Diagnostics
  • Treatments
By Product Type
  • Nanoparticles
    • Metal and Metal Oxide Nanoparticles
    • Liposomes
    • Polymers and Polymer Drug Conjugates
    • Hydrogel Nanoparticles
    • Dendrimers
    • Inorganic Nanoparticles
  • Nano-shells
  • Nanotubes
  • Nanodevices
By Indication
  • Oncological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Orthopedic Disorders
  • Neurological Diseases
  • Urological Diseases
  • Ophthalmological Diseases
  • Immunological Diseases
  • Others
By End User
  • Hospitals
  • Specialty Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Camurus AB, BlueWillow Biologics, EyePoint Pharmaceuticals, Cristal Therapeutics, AbbVie Inc., EnColl Corporation, CYTIMMUNE SCIENCES, Inc., Aquanova AG, Ceramisphere Health Pty Limited, Celgene, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NANOMEDICINE FOR DRUG DELIVERY MARKET, BY MODALITY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Modality

    • 4.2. Diagnostics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Treatments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: NANOMEDICINE FOR DRUG DELIVERY MARKET, BY PRODUCT TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product Type

    • 5.2. Nanoparticles

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

      • 5.2.4. Metal and Metal Oxide Nanoparticles

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Liposomes

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Polymers and Polymer Drug Conjugates

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Hydrogel Nanoparticles

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Dendrimers

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Inorganic Nanoparticles

        • 5.2.4.1. Market Size and Forecast

    • 5.3. Nano-shells

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Nanotubes

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Nanodevices

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: NANOMEDICINE FOR DRUG DELIVERY MARKET, BY INDICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Indication

    • 6.2. Oncological Diseases

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Infectious Diseases

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Cardiovascular Diseases

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Orthopedic Disorders

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Neurological Diseases

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Urological Diseases

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

    • 6.8. Ophthalmological Diseases

      • 6.8.1. Key Market Trends, Growth Factors and Opportunities

      • 6.8.2. Market Size and Forecast, By Region

      • 6.8.3. Market Share Analysis, By Country

    • 6.9. Immunological Diseases

      • 6.9.1. Key Market Trends, Growth Factors and Opportunities

      • 6.9.2. Market Size and Forecast, By Region

      • 6.9.3. Market Share Analysis, By Country

    • 6.10. Others

      • 6.10.1. Key Market Trends, Growth Factors and Opportunities

      • 6.10.2. Market Size and Forecast, By Region

      • 6.10.3. Market Share Analysis, By Country

  • CHAPTER 7: NANOMEDICINE FOR DRUG DELIVERY MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Specialty Clinics

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: NANOMEDICINE FOR DRUG DELIVERY MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Modality

      • 8.2.3. Market Size and Forecast, By Product Type

      • 8.2.4. Market Size and Forecast, By Indication

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Nanomedicine For Drug Delivery Market

        • 8.2.7.1. Market Size and Forecast, By Modality
        • 8.2.7.2. Market Size and Forecast, By Product Type
        • 8.2.7.3. Market Size and Forecast, By Indication
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Nanomedicine For Drug Delivery Market

        • 8.2.8.1. Market Size and Forecast, By Modality
        • 8.2.8.2. Market Size and Forecast, By Product Type
        • 8.2.8.3. Market Size and Forecast, By Indication
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Nanomedicine For Drug Delivery Market

        • 8.2.9.1. Market Size and Forecast, By Modality
        • 8.2.9.2. Market Size and Forecast, By Product Type
        • 8.2.9.3. Market Size and Forecast, By Indication
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Modality

      • 8.3.3. Market Size and Forecast, By Product Type

      • 8.3.4. Market Size and Forecast, By Indication

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Nanomedicine For Drug Delivery Market

        • 8.3.7.1. Market Size and Forecast, By Modality
        • 8.3.7.2. Market Size and Forecast, By Product Type
        • 8.3.7.3. Market Size and Forecast, By Indication
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Nanomedicine For Drug Delivery Market

        • 8.3.8.1. Market Size and Forecast, By Modality
        • 8.3.8.2. Market Size and Forecast, By Product Type
        • 8.3.8.3. Market Size and Forecast, By Indication
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Nanomedicine For Drug Delivery Market

        • 8.3.9.1. Market Size and Forecast, By Modality
        • 8.3.9.2. Market Size and Forecast, By Product Type
        • 8.3.9.3. Market Size and Forecast, By Indication
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Nanomedicine For Drug Delivery Market

        • 8.3.10.1. Market Size and Forecast, By Modality
        • 8.3.10.2. Market Size and Forecast, By Product Type
        • 8.3.10.3. Market Size and Forecast, By Indication
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Nanomedicine For Drug Delivery Market

        • 8.3.11.1. Market Size and Forecast, By Modality
        • 8.3.11.2. Market Size and Forecast, By Product Type
        • 8.3.11.3. Market Size and Forecast, By Indication
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Nanomedicine For Drug Delivery Market

        • 8.3.12.1. Market Size and Forecast, By Modality
        • 8.3.12.2. Market Size and Forecast, By Product Type
        • 8.3.12.3. Market Size and Forecast, By Indication
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Nanomedicine For Drug Delivery Market

        • 8.3.13.1. Market Size and Forecast, By Modality
        • 8.3.13.2. Market Size and Forecast, By Product Type
        • 8.3.13.3. Market Size and Forecast, By Indication
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Modality

      • 8.4.3. Market Size and Forecast, By Product Type

      • 8.4.4. Market Size and Forecast, By Indication

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Nanomedicine For Drug Delivery Market

        • 8.4.7.1. Market Size and Forecast, By Modality
        • 8.4.7.2. Market Size and Forecast, By Product Type
        • 8.4.7.3. Market Size and Forecast, By Indication
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Nanomedicine For Drug Delivery Market

        • 8.4.8.1. Market Size and Forecast, By Modality
        • 8.4.8.2. Market Size and Forecast, By Product Type
        • 8.4.8.3. Market Size and Forecast, By Indication
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Nanomedicine For Drug Delivery Market

        • 8.4.9.1. Market Size and Forecast, By Modality
        • 8.4.9.2. Market Size and Forecast, By Product Type
        • 8.4.9.3. Market Size and Forecast, By Indication
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Nanomedicine For Drug Delivery Market

        • 8.4.10.1. Market Size and Forecast, By Modality
        • 8.4.10.2. Market Size and Forecast, By Product Type
        • 8.4.10.3. Market Size and Forecast, By Indication
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Nanomedicine For Drug Delivery Market

        • 8.4.11.1. Market Size and Forecast, By Modality
        • 8.4.11.2. Market Size and Forecast, By Product Type
        • 8.4.11.3. Market Size and Forecast, By Indication
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Nanomedicine For Drug Delivery Market

        • 8.4.12.1. Market Size and Forecast, By Modality
        • 8.4.12.2. Market Size and Forecast, By Product Type
        • 8.4.12.3. Market Size and Forecast, By Indication
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Nanomedicine For Drug Delivery Market

        • 8.4.13.1. Market Size and Forecast, By Modality
        • 8.4.13.2. Market Size and Forecast, By Product Type
        • 8.4.13.3. Market Size and Forecast, By Indication
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Nanomedicine For Drug Delivery Market

        • 8.4.14.1. Market Size and Forecast, By Modality
        • 8.4.14.2. Market Size and Forecast, By Product Type
        • 8.4.14.3. Market Size and Forecast, By Indication
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Nanomedicine For Drug Delivery Market

        • 8.4.15.1. Market Size and Forecast, By Modality
        • 8.4.15.2. Market Size and Forecast, By Product Type
        • 8.4.15.3. Market Size and Forecast, By Indication
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Modality

      • 8.5.3. Market Size and Forecast, By Product Type

      • 8.5.4. Market Size and Forecast, By Indication

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Nanomedicine For Drug Delivery Market

        • 8.5.7.1. Market Size and Forecast, By Modality
        • 8.5.7.2. Market Size and Forecast, By Product Type
        • 8.5.7.3. Market Size and Forecast, By Indication
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Nanomedicine For Drug Delivery Market

        • 8.5.8.1. Market Size and Forecast, By Modality
        • 8.5.8.2. Market Size and Forecast, By Product Type
        • 8.5.8.3. Market Size and Forecast, By Indication
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Nanomedicine For Drug Delivery Market

        • 8.5.9.1. Market Size and Forecast, By Modality
        • 8.5.9.2. Market Size and Forecast, By Product Type
        • 8.5.9.3. Market Size and Forecast, By Indication
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Nanomedicine For Drug Delivery Market

        • 8.5.10.1. Market Size and Forecast, By Modality
        • 8.5.10.2. Market Size and Forecast, By Product Type
        • 8.5.10.3. Market Size and Forecast, By Indication
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Nanomedicine For Drug Delivery Market

        • 8.5.11.1. Market Size and Forecast, By Modality
        • 8.5.11.2. Market Size and Forecast, By Product Type
        • 8.5.11.3. Market Size and Forecast, By Indication
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Nanomedicine For Drug Delivery Market

        • 8.5.12.1. Market Size and Forecast, By Modality
        • 8.5.12.2. Market Size and Forecast, By Product Type
        • 8.5.12.3. Market Size and Forecast, By Indication
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. AbbVie Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Aquanova AG

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. BlueWillow Biologics

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Camurus AB

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Celgene, Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Ceramisphere Health Pty Limited

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Cristal Therapeutics

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. CYTIMMUNE SCIENCES, Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. EnColl Corporation

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. EyePoint Pharmaceuticals

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR TREATMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANOPARTICLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANO-SHELLS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANOTUBES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANODEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR ONCOLOGICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR UROLOGICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR OPHTHALMOLOGICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR IMMUNOLOGICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR SPECIALTY CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA NANOMEDICINE FOR DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. U.S. NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 30. U.S. NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 31. U.S. NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. U.S. NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. CANADA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 34. CANADA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. CANADA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. CANADA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. MEXICO NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. GERMANY NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 53. GERMANY NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. ITALY NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 55. ITALY NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. ITALY NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 57. ITALY NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. UK NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 63. UK NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. UK NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 65. UK NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. RUSSIA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 67. RUSSIA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. RUSSIA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 69. RUSSIA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 71. REST OF EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF EUROPE NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 76. ASIA-PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 77. ASIA-PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 78. ASIA-PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. CHINA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 80. CHINA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. CHINA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 82. CHINA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. JAPAN NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 84. JAPAN NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. JAPAN NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 86. JAPAN NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. INDIA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 88. INDIA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 89. INDIA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 90. INDIA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH KOREA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH KOREA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. AUSTRALIA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 96. AUSTRALIA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 97. AUSTRALIA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 98. AUSTRALIA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. THAILAND NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 100. THAILAND NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. THAILAND NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 102. THAILAND NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. MALAYSIA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 104. MALAYSIA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 105. MALAYSIA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 106. MALAYSIA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. INDONESIA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 108. INDONESIA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 109. INDONESIA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 110. INDONESIA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF ASIA PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 114. REST OF ASIA PACIFIC NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 117. LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 118. LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 119. LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 120. BRAZIL NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 121. BRAZIL NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 122. BRAZIL NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 123. BRAZIL NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 124. SOUTH AFRICA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 125. SOUTH AFRICA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 126. SOUTH AFRICA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 127. SOUTH AFRICA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 129. SAUDI ARABIA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 130. SAUDI ARABIA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 131. SAUDI ARABIA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 132. UAE NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 133. UAE NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 134. UAE NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 135. UAE NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. ARGENTINA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 137. ARGENTINA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 138. ARGENTINA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 139. ARGENTINA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY MODALITY, 2022-2032 ($MILLION)
  • TABLE 141. REST OF LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 142. REST OF LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 143. REST OF LAMEA NANOMEDICINE FOR DRUG DELIVERY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 144. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 145. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 146. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 147. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 148. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. AQUANOVA AG: KEY EXECUTIVES
  • TABLE 150. AQUANOVA AG: COMPANY SNAPSHOT
  • TABLE 151. AQUANOVA AG: OPERATING SEGMENTS
  • TABLE 152. AQUANOVA AG: PRODUCT PORTFOLIO
  • TABLE 153. AQUANOVA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. BLUEWILLOW BIOLOGICS: KEY EXECUTIVES
  • TABLE 155. BLUEWILLOW BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 156. BLUEWILLOW BIOLOGICS: OPERATING SEGMENTS
  • TABLE 157. BLUEWILLOW BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 158. BLUEWILLOW BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 159. CAMURUS AB: KEY EXECUTIVES
  • TABLE 160. CAMURUS AB: COMPANY SNAPSHOT
  • TABLE 161. CAMURUS AB: OPERATING SEGMENTS
  • TABLE 162. CAMURUS AB: PRODUCT PORTFOLIO
  • TABLE 163. CAMURUS AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 164. CELGENE, INC.: KEY EXECUTIVES
  • TABLE 165. CELGENE, INC.: COMPANY SNAPSHOT
  • TABLE 166. CELGENE, INC.: OPERATING SEGMENTS
  • TABLE 167. CELGENE, INC.: PRODUCT PORTFOLIO
  • TABLE 168. CELGENE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 169. CERAMISPHERE HEALTH PTY LIMITED: KEY EXECUTIVES
  • TABLE 170. CERAMISPHERE HEALTH PTY LIMITED: COMPANY SNAPSHOT
  • TABLE 171. CERAMISPHERE HEALTH PTY LIMITED: OPERATING SEGMENTS
  • TABLE 172. CERAMISPHERE HEALTH PTY LIMITED: PRODUCT PORTFOLIO
  • TABLE 173. CERAMISPHERE HEALTH PTY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174. CRISTAL THERAPEUTICS: KEY EXECUTIVES
  • TABLE 175. CRISTAL THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 176. CRISTAL THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 177. CRISTAL THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 178. CRISTAL THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 179. CYTIMMUNE SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 180. CYTIMMUNE SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 181. CYTIMMUNE SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 182. CYTIMMUNE SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 183. CYTIMMUNE SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 184. ENCOLL CORPORATION: KEY EXECUTIVES
  • TABLE 185. ENCOLL CORPORATION: COMPANY SNAPSHOT
  • TABLE 186. ENCOLL CORPORATION: OPERATING SEGMENTS
  • TABLE 187. ENCOLL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 188. ENCOLL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189. EYEPOINT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 190. EYEPOINT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 191. EYEPOINT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 192. EYEPOINT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 193. EYEPOINT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NANOMEDICINE FOR DRUG DELIVERY MARKET
  • FIGURE 3. SEGMENTATION NANOMEDICINE FOR DRUG DELIVERY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NANOMEDICINE FOR DRUG DELIVERY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNANOMEDICINE FOR DRUG DELIVERY MARKET
  • FIGURE 11. NANOMEDICINE FOR DRUG DELIVERY MARKET SEGMENTATION, BY BY MODALITY
  • FIGURE 12. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR TREATMENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NANOMEDICINE FOR DRUG DELIVERY MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 15. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANOPARTICLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANO-SHELLS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANOTUBES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NANODEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NANOMEDICINE FOR DRUG DELIVERY MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 20. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR ONCOLOGICAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR UROLOGICAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR OPHTHALMOLOGICAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR IMMUNOLOGICAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. NANOMEDICINE FOR DRUG DELIVERY MARKET SEGMENTATION, BY BY END USER
  • FIGURE 30. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. NANOMEDICINE FOR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 34. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 35. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 36. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 37. COMPETITIVE DASHBOARD
  • FIGURE 38. COMPETITIVE HEATMAP: NANOMEDICINE FOR DRUG DELIVERY MARKET
  • FIGURE 39. Top player positioning, 2022
  • FIGURE 40. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. AQUANOVA AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. AQUANOVA AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. AQUANOVA AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. BLUEWILLOW BIOLOGICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. BLUEWILLOW BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. BLUEWILLOW BIOLOGICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. CAMURUS AB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. CAMURUS AB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. CAMURUS AB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. CELGENE, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. CELGENE, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. CELGENE, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. CERAMISPHERE HEALTH PTY LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. CERAMISPHERE HEALTH PTY LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. CERAMISPHERE HEALTH PTY LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. CRISTAL THERAPEUTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. CRISTAL THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. CRISTAL THERAPEUTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. CYTIMMUNE SCIENCES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. CYTIMMUNE SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. CYTIMMUNE SCIENCES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. ENCOLL CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. ENCOLL CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. ENCOLL CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. EYEPOINT PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. EYEPOINT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. EYEPOINT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Nanomedicine For Drug Delivery Market

Start reading.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers